Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.45 |
| ▸ | LIPC | P11150 | 1/20 | 0.45 |
| ▸ | MLNR | O43193 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873126 | 0.92 | EPHX2 (0.54) | EPHX2MLNRSMN1; SMN2LMNAADRB2 | |
| SCHEMBL13873201 | 0.85 | EPHX2 (0.50) | EPHX2ACACBNAMPT | |
| SCHEMBL3377761 | 0.81 | GPR119 (0.57) | LIPGLIPC | |
| SCHEMBL19838626 | 0.81 | GPR119 (0.57) | LIPGLIPC | |
| SCHEMBL13873132 | 0.80 | EPHX2 (0.61) | EPHX2SMN1; SMN2LMNAADRB2CSNK1E | |
| SCHEMBL13873232 | 0.80 | EPHX2 (0.58) | EPHX2SMN1; SMN2LMNA | |
| SCHEMBL13873213 | 0.79 | EPHX2 (0.60) | EPHX2SMN1; SMN2LMNANAMPT | |
| SCHEMBL5534425 | 0.79 | GPR119 (0.55) | LIPGLIPC | |
| SCHEMBL10607824 | 0.79 | ADRB2 (0.50) | EPHX2LIPGLIPCMLNRSMN1; SMN2 | |
| SCHEMBL13873194 | 0.79 | EPHX2 (0.60) | EPHX2SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885LIPG 26/4885LIPC 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.